AI CuratorAI-generated

Research summary · 9 d ago

AI summary · not yet reviewedSubjects not reportedNot reportedPeer review unconfirmed

Findings from AHSCT Research in Severe MS Patients

In a study involving 24 patients with severe MS undergoing AHSCT, researchers found that the treatment decreased inflammatory cytokines and neuroinflammatory markers in serum and CSF over several years. They noted transient increases in certain cytokines post-treatment but these did not persist.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42809446)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Why it matters

This study indicates that AHSCT may effectively reduce inflammation related to MS, which is important for understanding potential outcomes of the treatment.

What this does not prove

However, the research does not demonstrate the specific mechanisms by which AHSCT works, and biomarker differences suggest complex immune responses.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Not reported
Participants / samples: 24 · Participants undergoing AHSCT in the HALT-MS trial
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Not reported
Relevant MS type: Not reported
Publication date: 2026-09-28
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidenceAutologous Hematopoietic Transplantation Reduces Brain Inflammatory and Axoglial Damage Biomarkers in Multiple Sclerosis. ↗DOI: 10.1212/nxi.0000000000200653

Supporting passages (8)

sample size24

sample size basisMETHODS: Longitudinal serum and CSF samples were obtained from 24 participants with severe MS undergoing AHSCT in the HALT-MS trial (NCT00288626), with serum collected at 9 time points from pretreatment through month 60 and CSF collected at 3 time points, including pretreatment, month 24, and month 48.

publication date2026-09-28

interventionAutologous hematopoietic stem cell transplantation (AHSCT)

primary endpointWe hypothesized that AHSCT would induce persistent decreases in inflammatory cytokines, chemokines, and axoglial damage biomarkers in serum and CSF.

follow upMETHODS: Longitudinal serum and CSF samples were obtained from 24 participants with severe MS undergoing AHSCT in the HALT-MS trial (NCT00288626), with serum collected at 9 time points from pretreatment through month 60 and CSF collected at 3 time points, including pretreatment, month 24, and month 48.

findingsRESULTS: AHSCT resulted in decreased expression of many proinflammatory cytokines, chemokines, and neuroinflammatory markers for several years in both serum and CSF, including neurofilament light chain (NfL).

limitationsBACKGROUND AND OBJECTIVES: Autologous hematopoietic stem cell transplantation (AHSCT) can induce long-lasting immune tolerance and disease quiescence in patients with severe multiple sclerosis (MS), but the underlying mechanisms are not well understood.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.